1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-52. [DOI:10.1056/NEJMra1406184] [PMID] [PMCID]
2. Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70-87. [DOI:10.1016/j.blre.2019.04.005] [PMID]
3. Estey E, Döhner H. Acute myeloid leukemia. Lancet. 2006;368(9550):1894-907. [DOI:10.1016/S0140-6736(06)69780-8] [PMID]
4. Krug U, Büchner T, Berdel WE, Müller-Tidow C. The treatment of elderly patients with acute myeloid leukemia. Dtsch Arztebl Int. 2011 Dec;108(51-52):863-70. [DOI:10.3238/arztebl.2011.0863] [PMID] [PMCID]
5. Justin D. Woods, Heidi D. Klepin; Geriatric Assessment in Acute Myeloid Leukemia. Acta Haematol 25 March 2024; 147 (2): 219–228. [DOI:10.1159/000535500]
6. Juliusson G, Lazarevic V, Hörstedt AS, Hagberg O, Höglund M. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119(17):3890-9. [DOI:10.1182/blood-2011-12-379008] [PMID] [PMCID]
7. Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593-606. [DOI:10.1016/S0140-6736(18)31041-9] [PMID] [PMCID]
8. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481-5. [DOI:10.1182/blood-2005-09-3724] [PMID] [PMCID]
9. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-47. [DOI:10.1182/blood-2016-08-733196] [PMID] [PMCID]
10. Rucker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, et al. TP53 alterations in acute myeloid leukemia with complex karyotypes correlate with specific copy number alterations, monosomal karyotypes, and dismal outcomes. Blood. 2012;119(9):2114-21. [DOI:10.1182/blood-2011-08-375758] [PMID]
11. Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Richard-Carpentier G, Jabbour E, et al. TP53 mutations in acute myeloid leukemia and myelodysplastic syndromes. Blood. 2019;134(4):251-65. [DOI:10.1182/blood-2019-130545]
12. Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukemia. Nature. 2015;518(7540):552-8. [DOI:10.1038/nature13968] [PMID] [PMCID]
13. Montalban-Bravo G. Outcomes of acute myeloid leukemia with myelodysplasia-related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020;95(8):891-9. [DOI:10.1002/ajh.25769] [PMID]
14. Falini B. Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia. Blood. 2023;142(2):327-38. [DOI:10.1002/ajh.26812] [PMID]
15. Chen J. Advances in genome-based acute myeloid leukemia classification: a comparative analysis of WHO-HAEM4R, WHO-HAEM5, and International Consensus Classification. Nat Rev Hematol. 2024;21(5):305-15. [DOI:10.1002/ajh.27249] [PMID]
16. Zhou S. A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria. J Clin Oncol. 2024;42(6):547-58. [PMID] [PMCID] [DOI:10.1182/bloodadvances.2023011869]
17. Hart D. Diagnosis of TP53-mutated myeloid disease by ICC and WHO classification. Blood Adv. 2024;8(3):112-20. [PMID] [PMCID] [DOI:10.1182/bloodadvances.2024014140]
18. Tashkandi S. Clinical relevance of subgrouping in TP53-mutated myelodysplastic neoplasms: insights from ICC and WHO classifications. Leukemia. 2024;38(7):1743-51.
19. Shah A. Evidence-based risk stratification of TP53-mutated myeloid neoplasms. J Clin Oncol. 2024;42(7):623-31. [DOI:10.1182/blood-2024-198269]
20. Ayala R, Rapado I, Onecha E, Martínez-Cuadrón D, Carreño-Tarragona G, Bergua JM, et al. The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the PETHEMA-FLUGAZA phase 3 clinical trial. Cancers (Basel). 2021;13(10):2401. [DOI:10.3390/cancers13102458] [PMID] [PMCID]
21. Bachelot A, Bouvier A, Riou J, Thepot S, Giltat A, Nunes Gomes C, et al. Relationship between comorbidities, mutational profile, and outcome after intensive chemotherapy in patients older than 60 years with acute myeloid leukemia: assessment of different risk scores. Am J Hematol. 2023;98(6):922-31. [DOI:10.1002/ajh.26917] [PMID]
22. Bories P, Prade N, Lagarde S, Cabarrou B, Largeaud L, Plenecassagnes J, et al. Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine. PLoS One. 2020;15(10):e0238795. [DOI:10.1371/journal.pone.0238795] [PMID] [PMCID]
23. Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman UU, et al. Impact of TP53 mutation status in elderly AML patients when adding all-trans retinoic acid or valproic acid to decitabine. Eur J Haematol. 2025;114(2):231-7. [DOI:10.1111/ejh.14304] [PMID] [PMCID]
24. Cai Z, Wei J, Chen Z, Wang H. High ROBO3 expression predicts poor survival in non-M3 acute myeloid leukemia. Exp Biol Med (Maywood). 2021;246(10):1184-97. [DOI:10.1177/1535370220988246] [PMID] [PMCID]
25. Chen EC, Li S, Eisfeld AK, Luskin MR, Mims A, Jones D, et al. Outcomes for patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2021; 27(6):479.e1-7. [DOI:10.1016/j.jtct.2021.02.028] [PMID]
26. Falk IJ, Willander K, Chaireti R, Lund J, Nahi H, Hermanson M, et al. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome. Eur J Haematol. 2015;94(4):355-62. [DOI:10.1111/ejh.12438] [PMID]
27. Fernandez-Pol S, Ma L, Ohgami RS, Arber DA. Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis. Mod Pathol. 2017;30(3):382-92. [DOI:10.1038/modpathol.2016.206] [PMID]
28. Fujiwara Y, Yamaguchi H, Yui S, Tokura T, Inai K, Onai D, et al. Importance of prognostic stratification via gene mutation analysis in elderly patients with acute myelogenous leukemia. Int J Lab Hematol. 2019;41(4):461-71. [DOI:10.1111/ijlh.13025] [PMID]
29. Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, et al. Mayo genetic risk models for newly diagnosed acute myeloid leukemia treated with venetoclax and hypomethylating agent. Am J Hematol. 2025;100(2):260-71. [DOI:10.1002/ajh.27564] [PMID] [PMCID]
30. Geissler K, Koristek Z, Del Castillo TB, Novák J, Rodríguez-Macías G, Metzelder SK, et al. Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: a randomised, crossover, registration, pharmacokinetics study. Br J Haematol. 2024;205(5):1734-45. [DOI:10.1111/bjh.19741] [PMID]
31. Grossmann V, Schnittger S, Kohlmann A, Eder C, Roller A, Dicker F, et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood. 2012;120(15):2963-72. [DOI:10.1182/blood-2012-03-419622] [PMID]
32. Guo Y, Niu Y, Liang H, Yang X, Jian J, Tang X, Liu B. A nomogram based on clinical features and molecular abnormalities for predicting the prognosis of patients with acute myeloid leukemia. Transl Cancer Res. 2023;12(12):3432-42. [DOI:10.21037/tcr-23-1192] [PMID] [PMCID]
33. Halik A, Tilgner M, Silva P, Estrada N, Altwasser R, Jahn E, et al. Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients. J Hematol Oncol. 2024;17(1):70. [DOI:10.1186/s13045-024-01590-1] [PMID] [PMCID]
34. Hernández-Sánchez A, González T, Sobas M, Sträng E, Castellani G, Abáigar M, et al. Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications-a HARMONY study. Leukemia. 2024;38(9):1929-37. [DOI:10.1038/s41375-024-02333-4] [PMID] [PMCID]
35. Hoff FW, Blum WG, Huang Y, Welkie RL, Swords RT, Traer E, et al. Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. Blood Adv. 2024;8(20):5297-305. [PMID] [PMCID] [DOI:10.1182/bloodadvances.2024013685]
36. Hong M, Zhu H, Sun Q, Zhu Y, Miao Y, Yang H, et al. Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML. Aging (Albany NY). 2020;12(7):5792-811. [DOI:10.18632/aging.102973] [PMID] [PMCID]
37. Hosono N, Chi S, Yamauchi T, Fukushima K, Shibayama H, Katagiri S, et al. Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01. Cancer Sci. 2023;114(5):2098-108. [DOI:10.1111/cas.15746] [PMID] [PMCID]
38. Hou HA, Chou WC, Kuo YY, Liu CY, Lin LI, Tseng MH, et al. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. Blood Cancer J. 2015;5(7):e331. [DOI:10.1038/bcj.2015.59] [PMID] [PMCID]
39. Hou Y, Zi J, Ge Z. High expression of RhoF predicts worse overall survival: a potential therapeutic target for non-M3 acute myeloid leukemia. J Cancer. 2021;12(18):5530-42. 1 comment on PubPeer (by: Litoria Paraewingi) [DOI:10.7150/jca.52648] [PMID] [PMCID]
40. Inokuchi K, Yamaguchi H, Hanawa H, Tanosaki S, Nakamura K, Tarusawa M, Miyake K, Shimada T, Dan K. Loss of DCC gene expression is of prognostic importance in acute myelogenous leukemia. Clin Cancer Res. 2002 Jun;8(6):1882-8. [PMID]
41. Itzykson R, Fournier E, Berthon C, Röllig C, Braun T, Marceau-Renaut A, et al. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 2021;138(7):507-19. [DOI:10.1182/blood.2021011103] [PMID]
42. Kang D, Jung J, Park S, Cho BS, Kim HJ, Kim Y, et al. Genetic characteristics according to subgroup of acute myeloid leukemia with myelodysplasia-related changes. J Clin Med. 2022;11(9):2538. [DOI:10.3390/jcm11092378] [PMID] [PMCID]
43. Ke P, Zhu Q, Xu T, Yang X, Wang Y, Qiu H, et al. Identification and validation of a 7-gene prognostic signature for adult acute myeloid leukemia based on aging-related genes. Aging (Albany NY). 2023;15(12):5826-53. [DOI:10.18632/aging.204843]
44. Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, et al. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021;127(20):3772-81. [DOI:10.1002/cncr.33689] [PMID] [PMCID]
45. Konopleva MY, Röllig C, Cavenagh J, Deeren D, Girshova L, Krauter J, et al. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial. Blood Adv. 2022;6(14):4147-56. [DOI:10.1182/bloodadvances.2021006303] [PMID] [PMCID]
46. Li J, Pei L, Liang S, Xu S, Wang Y, Wang X, et al. Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: a multi-center study from China. Cancer Med. 2023;12(8):9332-50. [DOI:10.1002/cam4.5690] [PMID] [PMCID]
47. Loke J, Labopin M, Craddock C, Cornelissen JJ, Labussière-Wallet H, Wagner-Drouet EM, et al. Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia. Cancer. 2022;128(15):2922-31. [DOI:10.1002/cncr.34268] [PMID] [PMCID]
48. Metafuni E, Amato V, Giammarco S, Bellesi S, Rossi M, Minnella G, et al. Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML. Front Oncol. 2022;12:939819. [DOI:10.3389/fonc.2022.939819] [PMID] [PMCID]
49. Middeke JM, Herold S, Rücker-Braun E, Berdel WE, Stelljes M, Kaufmann M, et al. TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2016;172(6):914-22. [DOI:10.1111/bjh.13912] [PMID]
50. Milosevic JD, Puda A, Malcovati L, Berg T, Hofbauer M, Stukalov A, et al. Clinical significance of genetic aberrations in secondary acute myeloid leukemia. Am J Hematol. 2012;87(11):1010-6. [DOI:10.1002/ajh.23309] [PMID]
51. Morsia E, McCullough K, Joshi M, Cook J, Alkhateeb HB, Al-Kali A, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol. 2020;95(12):1511-21. [DOI:10.1002/ajh.25978] [PMID]
52. Mrózek K, Eisfeld AK, Kohlschmidt J, Carroll AJ, Walker CJ, Nicolet D, et al. Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. Leukemia. 2019;33(7):1620-34. [DOI:10.1038/s41375-019-0390-3] [PMID] [PMCID]
53. Najima Y, Sadato D, Harada Y, Oboki K, Hirama C, Toya T, et al. Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT. Bone Marrow Transplant. 2021;56(2):334-46. [DOI:10.1038/s41409-020-01016-9] [PMID]
54. Ni J, Hong J, Long Z, Li Q, Xia R, Zeng Q. Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine-based chemotherapy. Int J Lab Hematol. 2020; 42(6):849-57. [DOI:10.1111/ijlh.13299] [PMID]
55. Ohgami RS, Ma L, Merker JD, Gotlib JR, Schrijver I, Zehnder JL, Arber DA. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Mod Pathol. 2015;28(5):706-14. [DOI:10.1038/modpathol.2014.160] [PMID] [PMCID]
56. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G, et al. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia are similar to de novo diseases. J Hematol Oncol. 2015;8:45. [DOI:10.1186/s13045-015-0139-z] [PMID] [PMCID]
57. Österroos A, Björklund M, Eriksson A, Lindberg J, Nilsson C, Mareschal S, et al. Integrated transcriptomic and genomic analysis improves prediction of complete remission and survival in elderly patients with acute myeloid leukemia. Blood Cancer J. 2020;10(6):67. [DOI:10.1038/s41408-020-0332-3] [PMID] [PMCID]
58. Patel SA, Cerny J, Gerber WK, Ramanathan M, Ediriwickrema A, Tanenbaum B, et al. Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions. EJHaem. 2023;4(4):1059-70. [DOI:10.1002/jha2.791] [PMID] [PMCID]
59. Sahasrabudhe K, Huang Y, Rebechi M, Elder P, Mims A, Wall S. Survival, response rates, and post-transplant outcomes in patients with acute myeloid leukemia aged 60-75 treated with high-intensity chemotherapy vs. lower-intensity targeted therapy. Front Oncol. 2022;12:1017194. [DOI:10.3389/fonc.2022.1017194] [PMID] [PMCID]
60. Shahswar R, Gabdoulline R, Krueger K, Wichmann M, Götze KS, Braitsch K, et al. A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents. Leukemia. 2025;39(2):402-12. [DOI:10.1038/s41375-024-02501-6] [PMID] [PMCID]
61. Shen K, Hu DY, Zhang ZB, Guo YS, Zhang FH, Chen SN. Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts. Int J Lab Hematol. 2023;45(3):344-52. [DOI:10.1111/ijlh.14030] [PMID]
62. Shimony S, Garcia JS, Keating J, Chen EC, Luskin MR, Stahl M, et al. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia. 2024;38(7):1494-500. [DOI:10.1038/s41375-024-02230-w] [PMID] [PMCID]
63. Stabellini N, Tomlinson B, Cullen J, Shanahan J, Waite K, Montero AJ, et al. Sex differences in adults with acute myeloid leukemia and the impact of sex on overall survival. Cancer Med. 2023;12(6):6711-21. [DOI:10.1002/cam4.5461] [PMID] [PMCID]
64. Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Adv. 2018;2(8):923-32. [PMID] [PMCID] [DOI:10.1182/bloodadvances.2018016121]
65. Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Adv. 2021;5(5):1552-64. [DOI:10.1182/bloodadvances.2020003734] [PMID] [PMCID]
66. Terada K, Yamaguchi H, Ueki T, Usuki K, Kobayashi Y, Tajika K, et al. Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor. Ann Hematol. 2018;97(1):51-61. [DOI:10.1007/s00277-017-3143-2] [PMID]
67. Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132(16):1703-13. [DOI:10.1182/blood-2018-02-829911] [PMID] [PMCID]
68. Venton G, Courtier F, Charbonnier A, D'Incan E, Saillard C, Mohty B, et al. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms. Am J Hematol. 2018;93(3):330-8. [DOI:10.1002/ajh.24973] [PMID]
69. Versluis J, Metzner M, Wang A, Gradowska P, Thomas A, Jakobsen NA, et al. Risk stratification in older intensively treated patients with AML. J Clin Oncol. 2024;42(34):4084-94. [DOI:10.1200/JCO.23.02631] [PMID] [PMCID]
70. Wang J, Wu Y, Uddin MN, Hao JP, Chen R, Xiong DQ, et al. Identification of MiR-93-5p targeted pathogenic markers in acute myeloid leukemia through integrative bioinformatics analysis and clinical validation. J Oncol. 2021;2021:5531736. [DOI:10.1155/2021/5531736] [PMID] [PMCID]
71. Wang P, Zhang Y, Cai Q, Long Q, Pan S, Zhou W, et al. Optimal combination of immune checkpoint and senescence molecule predicts adverse outcomes in patients with acute myeloid leukemia. Ann Med. 2023;55(1):2201507. [PMID] [PMCID] [DOI:10.1080/07853890.2023.2201507]
72. Weinberg OK, Siddon A, Madanat YF, Gagan J, Arber DA, Dal Cin P, et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022;6(9):2847-53. [DOI:10.1182/bloodadvances.2021006239] [PMID] [PMCID]
73. Wu M, Guo ZW, Huang GN, Ye YB. Features and impacts on the prognosis of gene mutations in patients with acute myeloid leukemia. Neoplasma. 2021;68(5):1072-8. [DOI:10.4149/neo_2021_201230N1426] [PMID]
74. Xie J, Chen K, Han H, Dong Q, Wang W. Establishment of tumor protein p53 mutation-based prognostic signatures for acute myeloid leukemia. Curr Res Transl Med. 2022;70(4):103347. [DOI:10.1016/j.retram.2022.103347] [PMID]
75. Yanada M, Yamamoto Y, Iba S, Okamoto A, Inaguma Y, Tokuda M, et al. TP53 mutations in older adults with acute myeloid leukemia. Int J Hematol. 2016; 103(4):429-35. [DOI:10.1007/s12185-016-1942-1] [PMID]
76. Yang L, Xu Q, Li J. Prognostic impact of ARHGAP43(SH3BP1) in acute myeloid leukemia. J Formos Med Assoc. 2024;123(9):992-1003. [DOI:10.1016/j.jfma.2024.04.002] [PMID]
77. Yoshida S, Onozawa M, Miyashita N, Kimura H, Takahashi S, Yokoyama S, et al. Clinical features of complex karyotype in newly diagnosed acute myeloid leukemia. Int J Hematol. 2023;117(4):544-52. [DOI:10.1007/s12185-022-03522-6] [PMID]
78. Yu G, Yin C, Wu F, Jiang L, Zheng Z, Xu D, et al. Gene mutation profile and risk stratification in AML1-ETO-positive acute myeloid leukemia based on next-generation sequencing. Oncol Rep. 2019;42(6):2333-44. [DOI:10.3892/or.2019.7375] [PMID] [PMCID]
79. Zhang L, Chen K, Li Y, Chen Q, Shi W, Ji T, et al. Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes. Hematology. 2023;28(1):2181773. [DOI:10.1080/16078454.2023.2181773] [PMID]
80. Zhang T, Bao X, Qiu H, Tang X, Han Y, Fu C, et al. Development of a nomogram for predicting the cumulative incidence of disease recurrence of AML after allo-HSCT. Front Oncol. 2021;11:732088. [DOI:10.3389/fonc.2021.732088] [PMID] [PMCID]
81. Zhao Q, Wang Y, Yu D, Leng JY, Zhao Y, Chu M, et al. Comprehensive analysis of ID genes reveals the clinical and prognostic value of ID3 expression in acute myeloid leukemia using bioinformatics identification and experimental validation. BMC Cancer. 2022;22(1):1229. [DOI:10.1186/s12885-022-10352-6] [PMID] [PMCID]
82. Zhou Q, Zhao D, Zarif M, Davidson MB, Minden MD, Tierens A, et al. A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria. Blood Adv. 2024;8(7):1760-71. [DOI:10.1182/bloodadvances.2023011869] [PMID] [PMCID]
83. Smith J, Johnson R, Lee M. A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria. Leuk Res. 2024;115:106789.
84. Zink F, Stacey SN, Norddahl GL, Frigge ML, Magnusson OT, Jonsdottir I, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017;130(6):742-52. [DOI:10.1182/blood-2017-02-769869] [PMID] [PMCID]
85. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367-76. [DOI:10.1182/blood-2014-11-610543] [PMID] [PMCID]
86. Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376(6):536-47. [DOI:10.1056/NEJMoa1611604] [PMID] [PMCID]
87. Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, et al. Role of TP53 mutations in the origin and evolution of therapy-related AML. Nature. 2015;518(7540):552-8. [DOI:10.1038/nature13968] [PMID] [PMCID]
88. Nadiminti K, Sidiqi MH, Meleveedu K, Alkhateeb HB, Hogan WJ, Litzow M, Patnaik M, Kumar S, Gertz M, Chen D, Shah MV. Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2021 Mar 19;11(3):63. [DOI:10.1038/s41408-021-00454-y] [PMID] [PMCID]
89. Castaño-Díez S, López-Guerra M, Bosch-Castañeda C, Bataller A, Charry P, Esteban D, Guijarro F, Jiménez-Vicente C, Castillo-Girón C, Cortes A, et al. Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes. Cancers. 2022; 14(17):4107. [DOI:10.3390/cancers14174107]
90. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-47. [DOI:10.1182/blood-2016-08-733196] [PMID] [PMCID]
91. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405. [DOI:10.1182/blood-2016-03-643544] [PMID]
92. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 2022 WHO classification of tumors of hematolymphoid tissues: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7): 1703-19. [DOI:10.1038/s41375-022-01613-1] [PMID] [PMCID]
93. Arber DA, Orazi A, Beau MM, Hasserjian RP, Borowitz MJ, Calvo KR, et al. International Consensus Classification of myeloid neoplasms and acute leukemia: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200-28. [DOI:10.1182/blood.2022015850] [PMID] [PMCID]
94. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022 Aug;97(8):1035-1043. [DOI:10.1002/ajh.26601] [PMID] [PMCID]
95. Pollyea DA, Pratz KW, Wei AH, Montesinos P, Schuh AC, Döhner H, et al. Venetoclax combinations in acute myeloid leukemia: clinical experience and future directions. Blood Rev. 2021;46:100733.
96. Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, Chyla B, Popovic R, Salem AH, Agarwal S, Xu T, Fakouhi KM, Humerickhouse R, Hong WJ, Hayslip J, Roboz GJ. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. J Clin Oncol. 2019 May 20;37(15):1277-1284. [DOI:10.1200/JCO.18.01600] [PMID] [PMCID]
97. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with azacitidine, decitabine, or low-dose cytarabine in newly diagnosed AML: VIALE-A and VIALE-C trials. N Engl J Med. 2020;383(7):617-29. [DOI:10.1056/NEJMoa2012971] [PMID]
98. Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R. Isocitrate dehydrogenase mutations in AML: clinical implications and targeted therapy. Leukemia. 2017;31(2):272-81. [DOI:10.1038/leu.2016.275] [PMID] [PMCID]
99. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-52. [DOI:10.1056/NEJMra1406184] [PMID] [PMCID]
100. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209-21. [DOI:10.1056/NEJMoa1516192] [PMID] [PMCID]
101. Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, et al. Advances in the treatment of acute myeloid leukemia: new drugs and promising agents. J Clin Oncol. 2020;38(16):1870-85.
102. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381(9865):484-95. [DOI:10.1016/S0140-6736(12)61727-9] [PMID]
